API | cariprazine

cariprazine (vraylar) Report issue

Small molecule Approved ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW

Cariprazine is an antipsychotic approved by FDA for the treatment of schizophrenia and bipolar I disorder. The drug has a unique clinical action which is explained by its ability to act on dopamine D3 receptors. Pharmacology studies revealed that cariprazine is a dual partial agonist of dopamine D2 and D3 receptors as well as serotonin 5HT1a, 2a and 2b receptors. ^NCATS

Chemistry

SMILES: CN(C)C(=O)N[C@@H]1CC[C@@H](CCN2CCN(CC2)c3cccc(Cl)c3Cl)CC1
InChIKey: KPWSJANDNDDRMB-QAQDUYKDSA-N
Mol. Mass: 427.42
ALogP: 4.34 Partition coefficient
ChEMBL Molecules:

cariprazine

cariprazine hydrochloride

More Chemistry

Pharmacology

Mechanisms of Action:
- D(2) dopamine receptor (Homo sapiens) ^UniProt
- D(3) dopamine receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Oral
Pro Drug: No

Drug Pricing (per unit)

United States

$30.0015 - $40.5178

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

cariprazine | cariprazine hcl | cariprazine hydrochloride | mp-214 | rgh-188 | rgh-188 hcl | trans-4-(2-(4-(2,3-dichlorophenyl)piperazine-1-yl)-ethyl)-n,n-dimethylcarbamoyl-cyclohexyl-amine hydrochloride | trans-n-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-n’,n’-dimethylurea hydrochloride | vraylar

Organizations (19)

Research & Development (17)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (12)

Approved Indications (2)

Bipolar Disorder

Schizophrenia

Experimental Indications - Clinical Trial Phases 1-4 (12)

Anxiety Disorders (Phase 2)

Attention Deficit Disorder with Hyperactivity (Phase 4)

Autism Spectrum Disorder (Phase 1)

Bipolar Disorder (Phase 4)

Cocaine-Related Disorders (Phase 2)

Cognitive Dysfunction (Phase 3)

Depression (Phase 3)

Depressive Disorder, Major (Phase 3)

Mania (Phase 3)

Opioid-Related Disorders (Phase 2)

Pharmacokinetics (Phase 1)

Schizophrenia (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 50
# of Trial Organizations: 17

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue